AI assistant
Hansa Biopharma — Major Shareholding Notification 2016
Mar 8, 2016
3057_rns_2016-03-08_b7e79e50-f2ee-4b68-a183-af922fce2bbb.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
- PRESS RELEASE - March 8, 2016
Farstorps Gård AB has divested Hansa Medical shares
Hansa Medical has been informed that a small group of long-term institutional investors have acquired shares from Farstorps Gård AB
Following the divestiture, Farstorps Gård AB holds approximately 1 million shares in Hansa Medical, equivalent to approximately 3 percent of the number of outstanding shares in Hansa Medical. Farstorps Gård AB has informed Hansa Medical that Farstorps Gård AB will remain a long-term shareholder in the company and that Farstorps Gård has committed not to divest any further shares within the next 12 months (a so called 12 month lock-up period).
The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on March 8, 2016 at 08.30 CET.
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.
For further information, please contact: Hansa Medical AB Göran Arvidson, CEO Mobile: +46 70-633 30 42
E-mail: [email protected]
www.hansamedical.com